Akari Therapeutics (AKTX) Competitors $1.00 -0.01 (-0.59%) Closing price 08/4/2025 03:51 PM EasternExtended Trading$0.70 -0.31 (-30.78%) As of 08:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AKTX vs. ACTU, FATE, CLLS, LXEO, CGEN, IOBT, TNYA, IKT, ANEB, and SPROShould you be buying Akari Therapeutics stock or one of its competitors? The main competitors of Akari Therapeutics include Actuate Therapeutics (ACTU), Fate Therapeutics (FATE), Cellectis (CLLS), Lexeo Therapeutics (LXEO), Compugen (CGEN), IO Biotech (IOBT), Tenaya Therapeutics (TNYA), Inhibikase Therapeutics (IKT), Anebulo Pharmaceuticals (ANEB), and Spero Therapeutics (SPRO). These companies are all part of the "pharmaceutical products" industry. Akari Therapeutics vs. Its Competitors Actuate Therapeutics Fate Therapeutics Cellectis Lexeo Therapeutics Compugen IO Biotech Tenaya Therapeutics Inhibikase Therapeutics Anebulo Pharmaceuticals Spero Therapeutics Akari Therapeutics (NASDAQ:AKTX) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability. Is AKTX or ACTU more profitable? Actuate Therapeutics' return on equity of 0.00% beat Akari Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Akari TherapeuticsN/A -213.59% -65.60% Actuate Therapeutics N/A N/A -339.73% Which has higher valuation and earnings, AKTX or ACTU? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkari TherapeuticsN/AN/A-$19.79MN/AN/AActuate TherapeuticsN/AN/A-$27.28MN/AN/A Do analysts rate AKTX or ACTU? Akari Therapeutics presently has a consensus price target of $5.00, indicating a potential upside of 398.01%. Actuate Therapeutics has a consensus price target of $20.50, indicating a potential upside of 189.96%. Given Akari Therapeutics' higher probable upside, equities research analysts clearly believe Akari Therapeutics is more favorable than Actuate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akari Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Actuate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of AKTX or ACTU? 5.1% of Akari Therapeutics shares are held by institutional investors. 38.1% of Akari Therapeutics shares are held by company insiders. Comparatively, 69.3% of Actuate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer AKTX or ACTU? In the previous week, Actuate Therapeutics had 1 more articles in the media than Akari Therapeutics. MarketBeat recorded 2 mentions for Actuate Therapeutics and 1 mentions for Akari Therapeutics. Akari Therapeutics' average media sentiment score of 0.00 equaled Actuate Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akari Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Actuate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAkari Therapeutics and Actuate Therapeutics tied by winning 4 of the 8 factors compared between the two stocks. Get Akari Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKTX vs. The Competition Export to ExcelMetricAkari TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$32.50M$3.02B$5.52B$9.35BDividend YieldN/A2.46%4.73%4.14%P/E RatioN/A18.0629.1424.41Price / SalesN/A183.41373.3878.86Price / CashN/A40.5624.4827.20Price / Book1.208.628.525.77Net Income-$19.79M-$54.98M$3.24B$264.99M7 Day Performance-7.03%-0.87%0.63%-0.68%1 Month Performance-14.92%16.08%7.95%7.08%1 Year Performance-72.03%14.18%30.89%23.80% Akari Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKTXAkari Therapeutics2.7232 of 5 stars$1.00-0.6%$5.00+398.0%-72.7%$32.50MN/A0.009ACTUActuate Therapeutics1.7187 of 5 stars$6.86-5.5%$20.50+198.8%N/A$142.44MN/A0.0010FATEFate Therapeutics3.9345 of 5 stars$1.30+4.8%$3.83+194.9%-77.1%$142.11M$13.63M-0.87550Positive NewsUpcoming EarningsAnalyst UpgradeCLLSCellectis2.0537 of 5 stars$2.85+13.1%$4.00+40.4%+44.5%$140.07M$49.22M-3.31290News CoverageEarnings ReportGap UpHigh Trading VolumeLXEOLexeo Therapeutics2.369 of 5 stars$4.26+3.1%$16.60+289.7%-64.0%$137.10M$650K-1.2958Upcoming EarningsCGENCompugen1.5072 of 5 stars$1.51-1.3%$4.00+164.9%-16.6%$136.53M$27.86M-9.4470News CoverageUpcoming EarningsIOBTIO Biotech3.0936 of 5 stars$2.40+16.5%$9.33+288.9%+76.2%$135.71MN/A-1.6130News CoverageUpcoming EarningsShort Interest ↑Gap UpHigh Trading VolumeTNYATenaya Therapeutics3.6581 of 5 stars$0.78-6.4%$6.25+701.4%-75.5%$135.53MN/A-0.67110News CoverageAnalyst RevisionIKTInhibikase Therapeutics1.6857 of 5 stars$1.77flat$6.50+267.2%+20.3%$131.59MN/A-0.666ANEBAnebulo Pharmaceuticals1.6116 of 5 stars$3.14-1.6%$5.50+75.2%+35.0%$131.06MN/A-12.084Gap DownSPROSpero Therapeutics3.8414 of 5 stars$2.30-1.3%$5.00+117.4%+72.5%$130.27M$47.98M-1.80150 Related Companies and Tools Related Companies Actuate Therapeutics Competitors Fate Therapeutics Competitors Cellectis Competitors Lexeo Therapeutics Competitors Compugen Competitors IO Biotech Competitors Tenaya Therapeutics Competitors Inhibikase Therapeutics Competitors Anebulo Pharmaceuticals Competitors Spero Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKTX) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWall Street Hates This Gold IRA Strategy—Here’s WhyWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Akari Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AKTX Stock Alerts